Clinical Report: Analysis of Fecal Metagenomics and Plasma Metabolomics in Rats

Overview

Revise to include specific alterations in gut microbiota and plasma metabolite profiles.

Background

Abemaciclib is a CDK4/6 inhibitor used in treating HR+/HER2− breast cancer, but it is associated with gastrointestinal toxicity, particularly diarrhea, affecting treatment adherence and patient quality of life. Understanding the mechanisms behind this side effect is critical for developing effective management strategies. Alterations in gut microbiota and metabolites may play a significant role in the pathophysiology of diarrhea, necessitating further investigation.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• Abemaciclib administration at 150 mg/kg/day induced Grade 3 diarrhea in all rats by day 12.
• Alterations in gut microbiota composition were observed, particularly in the abundance of Firmicutes and Bacteroidetes.
• Metabolomic analysis revealed significant changes in plasma metabolite profiles associated with diarrhea.
• The study emphasizes the importance of gut microbiota and metabolites in the pathophysiology of abemaciclib-induced diarrhea.
• Understanding these alterations may guide the development of targeted therapies for managing diarrhea in patients receiving abemaciclib.

Clinical Implications

Clinicians should be aware of the high incidence of diarrhea associated with abemaciclib treatment and consider monitoring gut microbiota and metabolites as part of patient management. Strategies aimed at restoring gut microbiota balance may improve patient outcomes and adherence to therapy.

Conclusion

The study provides valuable insights into the mechanisms of abemaciclib-induced diarrhea, highlighting the role of gut microbiota and metabolites. These findings may inform future therapeutic strategies to mitigate this common side effect.

References

1. Chrysin Reduces Inflammation and Alters Gut Microbiota in Mice with Dextran Sulfate-Induced Ulcerative Colitis
2. Resistant starch inhibits glycolysis via HK2 and mitigates colon tumor development induced by high-fructose corn syrup
3. Reduced Diversity of Antimicrobial Resistance Genes After Administration of Fecal Microbiota, Live-jslm (REBYOTA®): A Post Hoc Evaluation of PUNCH CD3
4. Influence of Blood Metabolites on the Relationship Between Gut Microbiome and Survival in Metastatic Colorectal Cancer with RAS/BRAF Mutations
5. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline - PMC
6. Where abemaciclib fits today
7. FDA Label for Abemaciclib